Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metenkefalin/tridecactide - Farmacija

Drug Profile

Metenkefalin/tridecactide - Farmacija

Alternative Names: EK-12; Enkorten

Latest Information Update: 22 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Farmacija
  • Developer Bosnalijek
  • Class Analgesics; Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Neuropeptides
  • Mechanism of Action Leukocyte stimulants; Opioid delta receptor agonists; Th1 cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase III Asthma
  • Phase II/III COVID 2019 infections
  • Phase II Crohn's disease; Ulcerative colitis
  • No development reported Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 22 Sep 2022 Metenkefalin/tridecactide is still in phase III and phase I/II trials for Multiple sclerosis and COVID-2019 infections in Turkey and Bosnia-Herzegovina (NCT03283397) (NCT04374032)
  • 01 May 2020 Phase-II/III clinical trials in COVID-2019 infections in Bosnia-Herzegovina (SC) (NCT04374032)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Bosnia-Herzegovina (SC, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top